Home › NDC Lookup › Ingredients › Amlodipine Besylate › 58151-0355-77
Norvasc amlodipine besylate 10 mg Tablet, 90-count — NDC 58151-0355-77 package photo

Norvasc amlodipine besylate 10 mg Tablet, 90-count

by Viatris Specialty LLC · 90 TABLET in 1 BOTTLE (58151-355-77)
NDC 58151-0355-77
🏷️ FDA NDC (as labeled) 58151-355-77 billing pads the product segment with a zero
This package
Contains90-count Cost per ea$11.98 NADAC Per package$1,077.82 / 90 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $11.47/unit · Part D plans $8.91/unit — full pricing hub ↓
Also comes in: 100 tablets 58151-0355-88
Rx only Brand On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 58151-355-77
Product NDC 58151-355
11-digit billing NDC 58151035577
NCPDP billing unit EA — each (per item)
RxCUI 197361, 212542, 212549, 212575, 308135, 308136
UNII 864V2Q084H
UPC 0358151354771
Application # NDA019787
SPL Set ID 7367289c-b0b0-466a-83e2-558e2985c29f
Established class (EPC) Calcium Channel Blocker; Dihydropyridine Calcium Channel Blocker
Mechanism of action Calcium Channel Antagonists; Cytochrome P450 3A Inhibitors
Chemical class Dihydropyridines
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-02-09
Route ORAL
Dosage form TABLET
Substance AMLODIPINE BESYLATE
GPI-14 34000003100340
GCN Seq No 016927
GCN 02682
HICL code 006494
Ingredient (HICL) Amlodipine Besylate
HIC1 code A
Therapeutic class — broad (HIC1) Cardiovascular System
HIC2 code A9
Therapeutic class — intermediate (HIC2) Calcium Antagonists
HIC3 code A9A
Therapeutic class — specific (HIC3) Calcium Channel Blocking Agents
AHFS code 24:08.92.00
AHFS class Vasodilating Agents, Misc (24:08)
FDB label name NORVASC 10 MG TABLET
FDB brand name Norvasc
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 58151-355-77 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 58151-0355-77. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Dihydropyridine Calcium Channel Blocker class.

Pharmacologic class Dihydropyridine Calcium Channel Blocker, Calcium Channel Blocker
Drug family (ATC) Renin-inhibitors, ACE inhibitors and calcium channel blockers, Dihydropyridine derivatives
How it works Calcium Channel Antagonists, Cytochrome P450 3A Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerViatris Specialty LLC
Application holderVIATRIS SPECIALTY LLC
FDA applicationNDA019787 (NDA)
Labeler code58151
First marketedFeb 2024
Product typeHuman Prescription Drug
Portfolio120 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name NORVASC 10 MG TABLET Ingredient Amlodipine Besylate
📖 What it is MedlinePlus · NLM

Amlodipine is used to treat high blood pressure and certain types of angina (chest pain) and coronary artery disease (narrowing of the blood vessels that supply blood to the heart). Amlodipine is in a class of medications called calcium channel blockers. It lowers blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. It controls chest pain by increasing the supply of blood to the heart. If taken regularly, amlodipine controls chest pain, but it does not stop chest pain once it starts. Your doctor may prescribe a different medication to take when you have ches...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Amlodipine is used mainly to treat two things: high blood pressure and certain types of chest pain (angina). For high blood pressure, it's approved for adults and children as young...
  • The most common one is swelling in your ankles or legs — this is dose-related, so it's more noticeable at higher doses, and women tend to notice it more than men. Dizziness, flushi...
  • What side effects should I expect, and which ones should I call about?
  • You can take amlodipine with or without food — it doesn't make a meaningful difference in how well it's absorbed. Because it stays in your system for a long time (a half-life of 30...
📖 Read our full Amlodipine guide →
2
Nutrient depletion considerations

Amlodipine Besylate may be associated with lower levels of 2 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Amlodipine Besylate nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color White
ShapeRound
ImprintNORVASC;10
Size1 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII L11K75P92J
    A mineral salt made from calcium and phosphate. It acts as a filler and binder in tablets to add bulk and help hold the medicine together in solid form.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII 5856J3G2A2
    A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $11.976 $1,077.82 / 90 tablets
Medicaid paysCMS SDUD · 12 mo $11.47 $1,032.71 / 90 tablets
Medicare drug plans payPart D · Q2 2026 $8.91 $802.13 / 90 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2026 May 2026 Jun 2026 Aug 2026 $11.994 $11.862
▲ Up 1% over the last 5 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Amlodipine Besylate 10 mg 00480-7168-98 Teva 90 tablets $0.015 AB Discontinued save 100%
Amlodipine Besylate 10 mg 00904-6371-61 Major 100 tablets $0.015 AB Availability likely save 100%
Amlodipine Besylate 10 mg 29300-0398-05 Unichem 500 tablets $0.015 AB Availability likely save 100%
amlodipine besylate 10 mg 59762-2135-01 Mylan 1000 tablets $0.015 AB Availability likely save 100%
Amlodipine Besylate 10 mg 60687-0496-01 American 100 tablets $0.015 AB Availability likely save 100%
Amlodipine Besylate 10 mg 67877-0199-05 Ascend 500 tablets $0.015 AB Availability likely save 100%
Amlodipine Besylate 10 mg 67877-0902-10 Ascend 1000 tablets $0.015 AB Availability likely save 100%
Amlodipine Besylate 10 mg 68180-0721-03 Lupin 1000 tablets $0.015 AB Availability likely save 100%
Amlodipine Besylate 10 mg 68645-0516-54 Legacy 30 tablets $0.015 AB Availability likely save 100%
Amlodipine Besylate 10 mg 68645-0580-54 Legacy 30 tablets $0.015 AB Availability likely save 100%
Amlodipine Besylate 10 mg 69097-0128-05 Cipla 90 tablets $0.015 AB Availability likely save 100%
AMLODIPINE BESYLATE 10 mg 69584-0023-09 Oxford 90 tablets $0.015 AB Availability likely save 100%
Amlodipine Besylate 10 mg 82009-0028-10 Quallent 1000 tablets $0.015 AB Availability likely save 100%
Amlodipine Besylate 10 mg 42806-0057-05 Epic 500 tablets $0.017 AB FDA listed save 100%
Amlodipine Besylate 10 mg 69097-0838-05 Cipla 90 tablets $0.019 AB FDA listed save 100%
Norvasc 10 mg 00069-1540-41 PFIZER 100 tablets $11.190 AB Discontinued save 7%
Norvasc 10 mgthis 58151-0355-77 Viatris 90 tablets $11.976 AB Availability likely —
Amlodipine Besylate 10 mg 00615-8431-05 NCS 15 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 42291-0027-10 AvKARE 1000 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 43063-0041-30 PD-Rx 30 tablets — AB FDA listed —
Amlodipine besylate 10 mg 43353-0989-30 Aphena 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 43489-0101-01 China 90 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 48433-0157-20 Safecor 100 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 50090-2581-00 A-S 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 50090-5354-00 A-S 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 50090-5355-00 A-S 90 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 50090-5550-00 A-S 90 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 50090-6808-00 A-S 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 50090-6809-00 A-S 90 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 51407-0951-10 GSMS, 1000 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 51655-0586-52 Northwind 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 51655-0869-52 Northwind 30 tablets — AB FDA listed —
amlodipine besylate 10 mg 52605-0043-10 POLYGEN 1000 tablets — AB Discontinued —
Amlodipine Besylate 10 mg 55154-6875-00 Cardinal 10 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 60760-0445-30 ST. 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 63187-0914-30 Proficient 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 65841-0622-01 Zydus 100 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 65862-0103-05 Aurobindo 500 tablets — — FDA listed —
Amlodipine Besylate 10 mg 68071-2305-02 NuCare 120 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 68071-2520-09 NuCare 90 tablets — AB FDA listed —
AMLODIPINE BESYLATE 10 mg 68071-3453-02 NuCare 120 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 68071-3698-02 NuCare 120 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 68382-0123-01 Zydus 100 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 68788-4085-01 Preferred 100 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 68788-7985-01 Preferred 100 tablets — AB FDA listed —
AMLODIPINE BESYLATE 10 mg 68788-8451-01 Preferred 100 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 68788-8543-01 Preferred 100 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 70518-0297-00 REMEDYREPACK 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 70518-2632-00 REMEDYREPACK 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 70518-4464-00 REMEDYREPACK 90 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 71205-0488-30 Proficient 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 71205-0506-30 Proficient 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 71335-0218-01 Bryant 30 tablets — AB FDA listed —
Amlodipine besylate 10 mg 71335-0843-01 Bryant 30 tablets — AB Discontinued —
Amlodipine Besylate 10 mg 71335-0945-01 Bryant 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 71335-1865-01 Bryant 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 71335-1887-01 Bryant 30 tablets — — Discontinued —
Amlodipine Besylate 10 mg 71335-2507-00 Bryant 7 tablets — AB FDA listed —
amlodipine besylate 10 mg 71610-0469-30 Aphena 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 71610-0620-30 Aphena 30 tablets — AB FDA listed —
AMLODIPINE BESYLATE 10 mg 71610-0830-30 Aphena 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 71610-0928-30 Aphena 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 71610-0938-30 Aphena 30 tablets — AB FDA listed —
AMLODIPINE BESYLATE 10 mg 71610-0978-30 Aphena 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 71610-0988-30 Aphena 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 72189-0529-90 Direct_Rx 90 tablets — AB FDA listed —
AMLODIPINE BESYLATE 10 mg 72789-0262-90 PD-Rx 90 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 72789-0516-30 PD-Rx 30 tablets — AB FDA listed —
Amlodipine besylate 10 mg 76282-0239-05 Exelan 500 tablets — AB FDA listed —
Amlodipine besylate 10 mg 76282-0509-05 Exelan 500 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 82804-0164-90 Proficient 90 tablets — AB FDA listed —
AMLODIPINE BESYLATE 10 mg 82804-0971-00 Proficient 100 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 82868-0031-90 Northwind 90 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 83209-0399-10 Boswell 10 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 87441-0016-01 Unit 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 68071-1980-02 NuCare 120 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 67296-2297-03 Redpharm 30 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 00615-8652-05 NCS 15 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 60687-0961-01 American 100 tablets — AB FDA listed —
Amlodipine Besylate 10 mg 67046-1157-03 Coupler 30 tablets — AB FDA listed —
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2024
On the market since
Feb 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 58151-0355-77, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
123
Units reimbursed last 4 qtrs
6.9K
Gross reimbursed last 4 qtrs
$79.1K
Avg / prescription
$643.14
Avg / unit
$11.4746
Latest quarter Q4 2025
26Rx
Medicaid pays / ea
$11.4746
gross reimbursed
vs
NADAC / ea
$11.9758
acquisition cost
=
Spread
−$0.5012
-4% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
100% FFS
Fee-for-service · 123 Rx Managed care · 0 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 6,270 units · 32.0 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: 624 units · 17.3 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
17.332.0
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 32.0 /100k
2 Connecticut 17.3 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
90 tablets this page58151-0355-77 118 Rx · $74,968
100 tablets58151-0355-88 No Medicaid data
Drug total (last 4 qtrs): 118 Rx · 6,474 units · $74,968 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Norvasc — the program that covers self-administered drugs. 2 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Norvasc. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$2.85M
Claims incl. refills
4.7K
Beneficiaries
3.2K
Spend / beneficiary
$904.68
Spend / claim
$606.65
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
58151-0355-77 You're viewing this 90 TABLET in 1 BOTTLE (58151-355-77) $11.98 / ea $1,077.82 2024-05-24 Active
58151-0355-88 100 BLISTER PACK in 1 BOX, UNIT-DOSE (58151-355-88) / 1 TABLET in 1 BLISTER PACK $11.98 / ea $1,197.58 2024-02-09 Active

This pack has the lowest per-ea cost of the 2 priced pack sizes ($11.98 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in NDC 58151-0355-77?
NDC 58151-0355-77 is a 90-count package — 90 tablet in 1 bottle.
What is the difference between NDC 58151-0355-77 and NDC 58151-0355-88?
Both are Norvasc amlodipine besylate 10 mg Tablet — the drug itself is identical. NDC 58151-0355-77 is the 90-count package, while NDC 58151-0355-88 is the 100 tablets package.
What NDC number is used to bill for this package of Norvasc amlodipine besylate 10 mg Tablet?
Bill NDC 58151-0355-77 — the 11-digit billing format is 58151035577. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📋 Description
🎯 Indications and Usage ~3 min read ▾

1 INDICATIONS AND USAGE NORVASC is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) o NORVASC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal’s or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40%

1.1Hypertension NORVASC ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including NORVASC.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. NORVASC may be used alone or in combination with other antihypertensive agents.

1.2Coronary Artery Disease (CAD) Chronic Stable Angina NORVASC is indicated for the symptomatic treatment of chronic stable angina. NORVASC may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) NORVASC is indicated for the treatment of confirmed or suspected vasospastic angina.

NORVASC may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, NORVASC is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure.

⏱️ Dosage and Administration ~1 min read ▾

2 DOSAGE AND ADMINISTRATION • Adult recommended starting dose: 5 mg once daily with maximum dose 10 mg once daily. ( 2.1 ) o Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily. ( 2.1 ) • Pediatric starting dose: 2.5 mg to 5 mg once daily. ( 2.2 ) Important Limitation : Doses in excess of 5 mg daily have not been studied in pediatric patients. ( 2.2 )

2.1Adults The usual initial antihypertensive oral dose of NORVASC is 5 mg once daily, and the maximum dose is 10 mg once daily. Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding NORVASC to other antihypertensive therapy. Adjust dosage according to blood pressure goals.

In general, wait 7 to 14 days between titration steps. Titrate more rapidly, however, if clinically warranted, provided the patient is assessed frequently. Angina : The recommended dose for chronic stable or vasospastic angina is 5–10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency.

Most patients will require 10 mg for adequate effect. Coronary artery disease: The recommended dose range for patients with coronary artery disease is 5–10 mg once daily. In clinical studies, the majority of patients required 10 mg [see Clinical Studies (14.4) ] .

2.2Children The effective antihypertensive oral dose in pediatric patients ages 6–17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients [see Clinical Pharmacology (12.4) , Clinical Studies (14.1) ] .

💊 Dosage Forms and Strengths 80 words ▾

3 DOSAGE FORMS AND STRENGTHS Tablets: 2.5 mg white, diamond, flat-faced, beveled edged, with “NORVASC” on one side and “2.5” on the other Tablets: 5 mg white, elongated octagon, flat-faced, beveled edged, engraved with both “NORVASC” and “5” on one side and plain on the other Tablets: 10 mg white, round, flat-faced, beveled edged, engraved with both “NORVASC” and “10” on one side and plain on the other • Tablets: 2.5 mg, 5 mg, and 10 mg ( 3 )

⛔ Contraindications 20 words ▾

4 CONTRAINDICATIONS NORVASC is contraindicated in patients with known sensitivity to amlodipine. • Known sensitivity to amlodipine ( 4 )

⚠️ Warnings and Cautions 161 words ▾

5 WARNINGS AND PRECAUTIONS • Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, acute hypotension is unlikely. ( 5.1 ) • Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of NORVASC, particularly in patients with severe obstructive coronary artery disease. ( 5.2 ) • Titrate slowly in patients with severe hepatic impairment. ( 5.3 )

5.1Hypotension Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. Because of the gradual onset of action, acute hypotension is unlikely.

5.2Increased Angina or Myocardial Infarction Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of NORVASC, particularly in patients with severe obstructive coronary artery disease.

5.3Patients with Hepatic Failure Because NORVASC is extensively metabolized by the liver and the plasma elimination half‑life (t 1/2 ) is 56 hours in patients with impaired hepatic function, titrate slowly when administering NORVASC to patients with severe hepatic impairment.

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS Most common adverse reaction to amlodipine is edema which occurred in a dose related manner. Other adverse experiences not dose related but reported with an incidence >1.0% are fatigue, nausea, abdominal pain, and somnolence. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. NORVASC has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. In general, treatment with NORVASC was well‑tolerated at doses up to 10 mg daily.

Most adverse reactions reported during therapy with NORVASC were of mild or moderate severity. In controlled clinical trials directly comparing NORVASC (N=1730) at doses up to 10 mg to placebo (N=1250), discontinuation of NORVASC because of adverse reactions was required in only about 1.5% of patients and was not significantly different from placebo (about 1%). The most commonly reported side effects more frequent than placebo are reflected in the table below.

The incidence (%) of side effects that occurred in a dose related manner are as follows: Amlodipine Placebo 2.5 mg 5 mg 10 mg N=275 N=296 N=268 N=520 Edema 1.8 3.0 10.8

0.6Dizziness 1.1 3.4 3.4

1.5Flushing 0.7 1.4 2.6

0.0Palpitation 0.7 1.4 4.5

0.6Other adverse reactions that were not clearly dose related but were reported with an incidence greater than 1.0% in placebo‑controlled clinical trials include the following: NORVASC (%) Placebo (%) (N=1730) (N=1250) Fatigue 4.5

2.8Nausea 2.9

1.9Abdominal Pain 1.6

0.3Somnolence 1.4

0.6For several adverse experiences that appear to be drug and dose related, there was a greater incidence in women than men associated with amlodipine treatment as shown in the following table: NORVASC Placebo Male=% Female=% Male=% Female=% (N=1218) (N=512) (N=914) (N=336) Edema 5.6 14.6 1.4

5.1Flushing 1.5 4.5 0.3

0.9Palpitations 1.4 3.3 0.9

0.9Somnolence 1.3 1.6 0.8

0.3The following events occurred in <1% but >0.1% of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship: Cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, peripheral ischemia, syncope, tachycardia, vasculitis. Central and Peripheral Nervous System: hypoesthesia, neuropathy peripheral, paresthesia, tremor, vertigo.

Gastrointestinal: anorexia, constipation, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia. General: allergic reaction, asthenia, 1 back pain, hot flushes, malaise, pain, rigors, weight gain, weight decrease. Musculoskeletal System: arthralgia, arthrosis, muscle cramps, 1 myalgia.

Psychiatric: sexual dysfunction (male 1 and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization. Respiratory System: dyspnea, 1 epistaxis. Skin and Appendages: angioedema, erythema multiforme, pruritus, 1 rash, 1 rash erythematous, rash maculopapular.

Special Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus. Urinary System: micturition frequency, micturition disorder, nocturia. Autonomic Nervous System: dry mouth, sweating increased.

Metabolic and Nutritional: hyperglycemia, thirst. Hemopoietic: leukopenia, purpura, thrombocytopenia. 1 These events occurred in less than 1% in placebo‑controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies.

NORVASC therapy has not been associated with clinically significant changes in routine laboratory tests. No clinically relevant changes were no…

🔄 Drug Interactions ~2 min read ▾

7 DRUG INTERACTIONS • Do not exceed doses greater than 20 mg daily of simvastatin. ( 7.2 )

7.1Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A inhibitors to determine the need for dose adjustment [see Clinical Pharmacology (12.3) ] . CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine.

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. Sildenafil Monitor for hypotension when sildenafil is co-administered with amlodipine [see Clinical Pharmacology (12.2) ] .

7.2Impact of Amlodipine on Other Drugs Simvastatin Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily [see Clinical Pharmacology (12.3) ] . Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered.

Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended and adjust the dose when appropriate [see Clinical Pharmacology (12.3) ] .

Drug interactions Sildenafil When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect [see Drug Interactions (7.1) ] .

Drug interactions In vitro data indicate that amlodipine has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin. Impact of other drugs on amlodipine Co-administered cimetidine, magnesium-and aluminum hydroxide antacids, sildenafil, and grapefruit juice have no impact on the exposure to amlodipine. CYP3A inhibitors : Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure.

Erythromycin co-administration in healthy volunteers did not significantly change amlodipine systemic exposure. However, strong inhibitors of CYP3A (e.g., itraconazole, clarithromycin) may increase the plasma concentrations of amlodipine to a greater extent [see Drug Interactions (7.1) ] . Impact of amlodipine on other drugs Amlodipine is a weak inhibitor of CYP3A and may increase exposure to CYP3A substrates.

Co-administered amlodipine does not affect the exposure to atorvastatin, digoxin, ethanol and the warfarin prothrombin response time. Simvastatin : Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone [see Drug Interactions (7.2) ] . Cyclosporine : A prospective study in renal transplant patients (N=11) showed on an average of 40% increase in trough cyclosporine levels when concomitantly treated with amlodipine [see Drug Interactions (7.2) ] .

Tacrolimus : A prospective study in healthy Chinese volunteers (N=9) with CYP3A5 expressers showed a 2.5- to 4-fold increase in tacrolimus exposure when concomitantly administered with amlodipine compared to tacrolimus alone. This finding was not observed in CYP3A5 non-expressers (N= 6). However, a 3-fold increase in plasma exposure to tacrolimus in a renal transplant patient (CYP3A5 non-expresser) upon initiation of amlodipine for the treatment of post-transplant hypertension resulting in reduction of tacrolimus dose has been reported.

Irrespective of the CYP3A5 genotype status, the possibility of an interaction cannot be excluded with these drugs [see Drug Interactions (7.2) ] .

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS • Pediatric: Effect on patients less than 6 years old is not known. ( 8.4 ) • Geriatric: Start dosing at the low end of the dose range. ( 8.5 )

8.1Pregnancy Risk Summary The limited available data based on post-marketing reports with NORVASC use in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. There are risks to the mother and fetus associated with poorly controlled hypertension in pregnancy [see Clinical Considerations ] . In animal reproduction studies, there was no evidence of adverse developmental effects when pregnant rats and rabbits were treated orally with amlodipine maleate during organogenesis at doses approximately 10 and 20-times the maximum recommended human dose (MRHD), respectively.

However for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold). Amlodipine has been shown to prolong both the gestation period and the duration of labor in rats at this dose [see Data ]. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%‑20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section and post-partum hemorrhage).

Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Data Animal Data No evidence of teratogenicity or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses up to 10 mg amlodipine/kg/day (approximately 10 and 20 times the MRHD based on body surface area, respectively) during their respective periods of major organogenesis.

However for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5‑fold) in rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose.

8.2Lactation Risk Summary Limited available data from a published clinical lactation study reports that amlodipine is present in human milk at an estimated median relative infant dose of 4.2%. No adverse effects of amlodipine on the breastfed infant have been observed. There is no available information on the effects of amlodipine on milk production.

8.4Pediatric Use NORVASC (2.5 to 5 mg daily) is effective in lowering blood pressure in patients 6 to 17 years [see Clinical Studies (14.1) ] . Effect of NORVASC on blood pressure in patients less than 6 years of age is not known.

8.5Geriatric Use Clinical studies of NORVASC did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40–60%, and a lower initial dose may be required [see Dosage and Administr…

🤰 Pregnancy ~2 min read ▾

8.1Pregnancy Risk Summary The limited available data based on post-marketing reports with NORVASC use in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. There are risks to the mother and fetus associated with poorly controlled hypertension in pregnancy [see Clinical Considerations ] . In animal reproduction studies, there was no evidence of adverse developmental effects when pregnant rats and rabbits were treated orally with amlodipine maleate during organogenesis at doses approximately 10 and 20-times the maximum recommended human dose (MRHD), respectively.

However for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold). Amlodipine has been shown to prolong both the gestation period and the duration of labor in rats at this dose [see Data ]. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%‑20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section and post-partum hemorrhage).

Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Data Animal Data No evidence of teratogenicity or other embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses up to 10 mg amlodipine/kg/day (approximately 10 and 20 times the MRHD based on body surface area, respectively) during their respective periods of major organogenesis.

However for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5‑fold) in rats receiving amlodipine maleate at a dose equivalent to 10 mg amlodipine/kg/day for 14 days before mating and throughout mating and gestation. Amlodipine maleate has been shown to prolong both the gestation period and the duration of labor in rats at this dose.

🧒 Pediatric Use 44 words ▾

8.4Pediatric Use NORVASC (2.5 to 5 mg daily) is effective in lowering blood pressure in patients 6 to 17 years [see Clinical Studies (14.1) ] . Effect of NORVASC on blood pressure in patients less than 6 years of age is not known.

🧓 Geriatric Use 114 words ▾

8.5Geriatric Use Clinical studies of NORVASC did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40–60%, and a lower initial dose may be required [see Dosage and Administration (2.1) ] .

🆘 Overdosage 159 words ▾

10 OVERDOSAGE Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia. In humans, experience with intentional overdosage of NORVASC is limited. Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and 100 mg amlodipine/kg in mice and rats, respectively, caused deaths.

Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg or higher in dogs (11 or more times the maximum recommended human dose on a mg/m 2 basis) caused a marked peripheral vasodilation and hypotension. If massive overdose should occur, initiate active cardiac and respiratory monitoring. Frequent blood pressure measurements are essential.

Should hypotension occur, provide cardiovascular support including elevation of the extremities and the judicious administration of fluids. If hypotension remains unresponsive to these conservative measures, consider administration of vasopressors (such as phenylephrine) with attention to circulating volume and urine output. As NORVASC is highly protein bound, hemodialysis is not likely to be of benefit.

🧬 Clinical Pharmacology ~3 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow‑channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.

Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine.

Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following: Exertional Angina: In patients with exertional angina, NORVASC reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.

Vasospastic Angina: NORVASC has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro . This inhibition of coronary spasm is responsible for the effectiveness of NORVASC in vasospastic (Prinzmetal’s or variant) angina.

12.2Pharmacodynamics Hemodynamics: Following administration of therapeutic doses to patients with hypertension, NORVASC produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina.

With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with NORVASC is also correlated with the height of pretreatment elevation; thus, individuals with moderate hypertension (diastolic pressure 105–114 mmHg) had about a 50% greater response than patients with mild hypertension (diastolic pressure 90–104 mmHg).

Normotensive subjects experienced no clinically significant change in blood pressures (+1/–2 mmHg). In hypertensive patients with normal renal function, therapeutic doses of NORVASC resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or proteinuria. As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with NORVASC have generally demonstrated a small increase in cardiac index without significant in…

🧬 Mechanism of Action ~1 min read ▾

12.1Mechanism of Action Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow‑channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.

Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine.

Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following: Exertional Angina: In patients with exertional angina, NORVASC reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.

Vasospastic Angina: NORVASC has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro . This inhibition of coronary spasm is responsible for the effectiveness of NORVASC in vasospastic (Prinzmetal’s or variant) angina.

📦 How Supplied / Storage and Handling 216 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING 2.5 mg Tablets NORVASC – 2.5 mg Tablets (amlodipine besylate equivalent to 2.5 mg of amlodipine per tablet) are supplied as white, diamond, flat‑faced, beveled edged engraved with “NORVASC” on one side and “2.5” on the other side and supplied as follows: NDC 58151-353-77 Bottle of 90 5 mg Tablets NORVASC – 5 mg Tablets (amlodipine besylate equivalent to 5 mg of amlodipine per tablet) are white, elongated octagon, flat‑faced, beveled edged engraved with both “NORVASC” and “5” on one side and plain on the other side and supplied as follows: NDC 58151-354-77 Bottle of 90 NDC 58151-354-88 Unit Dose package of 100 NDC 58151-354-30 Bottle of 300 10 mg Tablets NORVASC – 10 mg Tablets (amlodipine besylate equivalent to 10 mg of amlodipine per tablet) are white, round, flat‑faced, beveled edged engraved with both “NORVASC” and “10” on one side and plain on the other side and supplied as follows: NDC 58151-355-77 Bottle of 90 NDC 58151-355-88 Unit Dose package of 100 Storage Store bottles at controlled room temperature, 59° to 86°F (15° to 30°C) and dispense in tight, light‑resistant containers (USP).

Distributed by: Viatris Specialty LLC Morgantown, WV 26505 U.S.A. © 2023 Viatris Inc. NORVASC is a registered trademark of Viatris Specialty LLC, a Viatris Company. UPJ:NRVSCT:R1p Revised: 2/2023

📋 Description 123 words ▾

11 DESCRIPTION NORVASC is the besylate salt of amlodipine, a long‑acting calcium channel blocker. Amlodipine besylate is chemically described as 3-Ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4‑(2‑chlorophenyl)‑1,4‑dihydro‑6‑methyl‑3,5‑pyridinedicarboxylate, monobenzenesulphonate. Its empirical formula is C 20 H 25 CIN 2 O 5 •C 6 H 6 O 3 S, and its structural formula is: Amlodipine besylate is a white crystalline powder with a molecular weight of 567.1.

It is slightly soluble in water and sparingly soluble in ethanol. NORVASC (amlodipine besylate) Tablets are formulated as white tablets equivalent to 2.5, 5, and 10 mg of amlodipine for oral administration. In addition to the active ingredient, amlodipine besylate, each tablet contains the following inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate.

Amlodipine Besylate Structural Formula

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 58151-0354-30 · Viatris 58151-0367-56 · Viatris →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.